$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
What versions of dabrafenib are there?
2026-02-01 22:25:32
Check Details
What are the side effects of Lorlatinib/lorlatinib?
2026-02-01 22:25:32
Check Details
Lorlatinib/lorlatinib (lorlatinib) launch time
2026-02-01 22:25:32
Check Details
Lorlatinib/Lorlatinib (Lorlatinib) is the first generation of targeted drugs
2026-02-01 22:25:32
Check Details
Lorlatinib/Lorlatinib resistance time
2026-02-01 22:25:32
Check Details
Lorlatinib/Lorlatinib Instructions
2026-02-01 22:25:32
Check Details
How much does the targeted drug Lorlatinib cost?
2026-02-01 22:25:32
Check Details
Has Lorlatinib/lorlatinib (Lorlatinib) targeted drug been included in medical insurance?
2026-02-01 22:25:32
Check Details
Lorlatinib/lorlatinib usage and dosage
2026-02-01 22:25:32
Check Details
What cancer does Lorlatinib treat?
2026-02-01 22:25:32
Check Details
How much does the Indian generic drug of Lorlatinib cost?
2026-02-01 22:25:32
Check Details
Lorlatinib/lorlatinib side effects
2026-02-01 22:25:32
Check Details
1
2
...
365
366
367
368
369
370
371
...
10222
10223
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Lorlatinib: Mechanism, Advantages, and Key Considerations of Third-Generation ALK Inhibitor Therapy in ALK-Positive NSCLC
2
FDA Approves Subcutaneous Isatuximab (Sarclisa) for Multiple Myeloma: A New Administration Option
3
Pemigatinib Side Effects Explained: Managing Adverse Reactions of FGFR-Targeted Therapy in Cholangiocarcinoma
4
Selpercatinib: Before or After Meals? A Complete Guide to RET-Targeted Therapy Administration
5
Mitotane for Adrenocortical Carcinoma: Dosing Guidelines and Therapeutic Drug Monitoring
6
Vadadustat: Clinical Evidence and Patient Benefits of an Oral HIF-PHI for CKD-Related Anemia
7
Ponatinib vs. Olverembatinib: A Multidimensional Comparison of Third-Generation BCR-ABL Inhibitors
8
Leflunomide and Ocular Adverse Effects: Risk Awareness and Clinical Guidance
9
Clinical Management of Acquired Resistance to Garsorasib (KRAS G12C Inhibitor)
10
Chemical Structure of Capivasertib: A Novel AKT Inhibitor
11
Avatrombopag (Doptelet): Oral TPO-RA for Multiple Thrombocytopenia Types
12
Capivasertib: An AKT Inhibitor for Breast and Prostate Cancer